A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin’s lymphoma, and glioblastoma. Here, we report a case of severe drug-induced liver injury requiring liver transplantation due to vanishing bile duct syndrome (VBDS) after exposure to pexidartinib in the I-SPY 2 Trial, a phase 2 multicenter randomized neoadjuvant chemotherapy trial in patients with Stage II–III breast cancer. We also review the current literature on this rare, idiosyncratic, and potentially life-threatening entity.
Funding Information
  • Foundation for the National Institutes of Health
  • Quantum Leap Healthcare Collaborative NCI Center for Biomedical Informatics and Information Technology

This publication has 40 references indexed in Scilit: